Status:

TERMINATED

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Lead Sponsor:

Pfizer

Conditions:

Breast Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive and negative breast and gastric cancer (HER2 positive only a...

Eligibility Criteria

Inclusion

  • HER2 positive breast cancer or gastric cancer that is resistant to standard therapy or for which no standard therapy is available (Part 1A only)
  • HER2 positive and negative breast cancer (Part 2A)
  • HER2 negative breast cancer (Part 1B \& Part 2B)
  • Performance status of 0 or 1
  • Adequate bone marrow, kidney and liver function

Exclusion

  • Known CNS disease including, but not limited to, metastases
  • History of exposure to certain cumulative doses of anthracyclines
  • Grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy
  • Active and clinically significant bacterial, fungal, or viral infection
  • Abnormal cardiac function defined by a LVEF \<50% by ECHO or MUGA
  • Patients with previous history or active interstitial lung disease or pulmonary fibrosis, or a history of other clinically significant lung diseases

Key Trial Info

Start Date :

November 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2021

Estimated Enrollment :

95 Patients enrolled

Trial Details

Trial ID

NCT03284723

Start Date

November 1 2017

End Date

August 31 2021

Last Update

September 3 2024

Active Locations (46)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 12 (46 locations)

1

Banner-University Medical Center Tucson

Tucson, Arizona, United States, 85719

2

The University of Arizona Cancer Center - North Campus

Tucson, Arizona, United States, 85719

3

The University of Arizona Cancer Center

Tucson, Arizona, United States, 85724

4

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Los Angeles, California, United States, 90048